A Growing, Diversified Portfolio of Generic Products
On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.
About Impax Generics
Impax Generics develops, manufactures and commercializes complex oral solids and alternative dosage form products across a broad range of therapeutic categories. Our portfolio currently contains more than 60 marketed products, many of which represent difficult-to-manufacture products or products that have a high barrier to entry. Our products are available at pharmacies within the United States and the Commonwealth of Puerto Rico.